Hematopoietic stem cell gene therapy: progress toward therapeutic targets

Area of Science:

• * Hematology
• * Gene Therapy
• * Stem Cell Biology

Background:

• * Hematopoietic stem cell (HSC) gene therapy is a rapidly advancing field, paralleling developments in stem cell transplantation.
• * Significant progress has been made over the past two decades in gene transfer and expression techniques for HSCs.
• * Preclinical models demonstrate efficient gene expression in repopulating stem cells across multiple species.

Purpose of the Study:

• * To review the advancements and clinical applications of gene therapy using hematopoietic stem cells.
• * To discuss the viral vectors and therapeutic genes employed in HSC gene therapy.
• * To highlight the role of in vivo stem cell selection and future directions in the field.

Main Methods:

• * Utilization of modified murine oncoretroviruses and lentiviruses for gene transfer into HSCs.
• * Clinical application of therapeutic genes for severe combined immunodeficiency, common variable gamma chain immunodeficiency, chronic granulomatous disease, Hurler's, and Gaucher's Disease.
• * Development of drug resistance selection methods, such as using the MGMT gene, to enhance therapeutic success.

Main Results:

• * Oncoretroviruses and lentiviruses successfully transmit genes into HSCs, enabling expression post-transplantation.
• * Clinical trials using oncoretroviruses showed modest success, with notable exceptions in immunodeficiency patients achieving partial T-cell chimerism.
• * Drug resistance selection, particularly with the MGMT gene, has been developed and shown to be safe, aiding in vivo stem cell selection.

Conclusions:

• * Hematopoietic stem cell gene therapy holds significant therapeutic potential for various genetic disorders.
• * In vivo stem cell selection is crucial for successful therapeutic outcomes.
• * Future clinical trials will explore combined drug resistance and therapeutic gene strategies, alongside safety-modified lentiviruses.